Exact Mass: 445.2900194
Exact Mass Matches: 445.2900194
Found 500 metabolites which its exact mass value is equals to given mass value 445.2900194,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Dynorphin B (10-13)
Dynorphin B (10-13) is fraction of Dynorphin B with only Lys-Val-Val-Thr peptide chain. Dynorphin B is an agonist of nuclear opioid receptors coupling nuclear protein Kinase C activation to the transcription of cardiogenic genes in GTR1 embryonic stem cells. Dynorphin B is a form of dynorphin.Dynorphins are a class of opioid peptides that arise from the precursor protein prodynorphin. When prodynorphin is cleaved during processing by proprotein convertase 2 (PC2), multiple active peptides are released: dynorphin A, dynorphin B, and a/b-neo-endorphin. Depolarization of a neuron containing prodynorphin stimulates PC2 processing, which occurs within synaptic vesicles in the presynaptic terminal. Occasionally, prodynorphin is not fully processed, leading to the release of "big dynorphin."This 32-amino acid molecule consists of both dynorphin A and dynorphin B.Dynorphin A, dynorphin B, and big dynorphin all contain a high proportion of basic amino acid residues, in particular lysine and arginine (29.4\\%, 23.1\\%, and 31.2\\% basic residues, respectively), as well as many hydrophobic residues (41.2\\%, 30.8\\%, and 34.4\\% hydrophobic residues, respectively). Although dynorphins are found widely distributed in the CNS, they have the highest concentrations in the hypothalamus, medulla, pons, midbrain, and spinal cord. Dynorphins are stored in large (80-120 nm diameter) dense-core vesicles that are considerably larger than vesicles storing neurotransmitters. These large dense-core vesicles differ from small synaptic vesicles in that a more intense and prolonged stimulus is needed to cause the large vesicles to release their contents into the synaptic cleft. Dense-core vesicle storage is characteristic of opioid peptides storage. The first clues to the functionality of dynorphins came from Goldstein et al. in their work with opioid peptides. The group discovered an endogenous opioid peptide in the porcine pituitary that proved difficult to isolate. By sequencing the first 13 amino acids of the peptide, they created a synthetic version of the peptide with a similar potency to the natural peptide. Goldstein et al. applied the synthetic peptide to the guinea ileum longitudinal muscle and found it to be an extraordinarily potent opioid peptide. The peptide was called dynorphin (from the Greek dynamis=power) to describe its potency. Dynorphins exert their effects primarily through the κ-opioid receptor (KOR), a G-protein-coupled receptor. Two subtypes of KORs have been identified: K1 and K2. Although KOR is the primary receptor for all dynorphins, the peptides do have some affinity for the μ-opioid receptor (MOR), d-opioid receptor (DOR), N-methyl-D-aspartic acid (NMDA)-type glutamate receptor. Different dynorphins show different receptor selectivities and potencies at receptors. Big dynorphin and dynorphin A have the same selectivity for human KOR, but dynorphin A is more selective for KOR over MOR and DOR than is big dynorphin. Big dynorphin is more potent at KORs than is dynorphin A. Both big dynorphin and dynorphin A are more potent and more selective than dynorphin B (Wikipedia). Dynorphin B (10-13) is fraction of Dynorphin B with only Lys-Val-Val-Thr peptide chain.
N-Oleoyl tyrosine
C27H43NO4 (445.31919180000006)
N-oleoyl tyrosine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Oleic acid amide of Tyrosine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Oleoyl tyrosine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Oleoyl tyrosine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
7-Hydroxyhexadecanedioylcarnitine
C23H43NO7 (445.30393680000003)
7-Hydroxyhexadecanedioylcarnitine is an acylcarnitine. More specifically, it is an 7-hydroxyhexadecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Hydroxyhexadecanedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-Hydroxyhexadecanedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
8-Hydroxyhexadecanedioylcarnitine
C23H43NO7 (445.30393680000003)
8-Hydroxyhexadecanedioylcarnitine is an acylcarnitine. More specifically, it is an 8-hydroxyhexadecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Hydroxyhexadecanedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 8-Hydroxyhexadecanedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
4-Hydroxyhexadecanedioylcarnitine
C23H43NO7 (445.30393680000003)
4-Hydroxyhexadecanedioylcarnitine is an acylcarnitine. More specifically, it is an 4-hydroxyhexadecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hydroxyhexadecanedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 4-Hydroxyhexadecanedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
6-Hydroxyhexadecanedioylcarnitine
C23H43NO7 (445.30393680000003)
6-Hydroxyhexadecanedioylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxyhexadecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Hydroxyhexadecanedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 6-Hydroxyhexadecanedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Hydroxyhexadecanedioylcarnitine
C23H43NO7 (445.30393680000003)
3-Hydroxyhexadecanedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyhexadecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxyhexadecanedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Hydroxyhexadecanedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
5-Hydroxyhexadecanedioylcarnitine
C23H43NO7 (445.30393680000003)
5-Hydroxyhexadecanedioylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxyhexadecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxyhexadecanedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-Hydroxyhexadecanedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z,8Z,10E,12E,14Z)-Icosa-5,8,10,12,14-pentaenoylcarnitine
C27H43NO4 (445.31919180000006)
(5Z,8Z,10E,12E,14Z)-Icosa-5,8,10,12,14-pentaenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,8Z,10E,12E,14Z)-icosa-5,8,10,12,14-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,8Z,10E,12E,14Z)-Icosa-5,8,10,12,14-pentaenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z,8Z,10E,12E,14Z)-Icosa-5,8,10,12,14-pentaenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z,8Z,11Z,14Z,17Z)-Icosa-5,8,11,14,17-pentaenoylcarnitine
C27H43NO4 (445.31919180000006)
(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2S,3S,5S,8S,9S,10S,13S,14S,17S)-17-Acetyl-2-(2,2-dimethylmorpholino)-3-hydroxy-10,13-dimethylhexadecahydro-11H-cyclopenta[a]phenanthren-11-one
C27H43NO4 (445.31919180000006)
Ile Val Ser Lys
Ile Ala Lys Asp
C19H35N5O7 (445.25363600000003)
Asp Ile Ala Lys
C19H35N5O7 (445.25363600000003)
Ala Asp Ile Lys
C19H35N5O7 (445.25363600000003)
Ala Asp Lys Ile
C19H35N5O7 (445.25363600000003)
Ala Asp Lys Leu
C19H35N5O7 (445.25363600000003)
Ala Asp Leu Lys
C19H35N5O7 (445.25363600000003)
Ala Glu Lys Val
C19H35N5O7 (445.25363600000003)
Ala Glu Val Lys
C19H35N5O7 (445.25363600000003)
Ala Ile Asp Lys
C19H35N5O7 (445.25363600000003)
Ala Ile Lys Asp
C19H35N5O7 (445.25363600000003)
Ala Ile Arg Ser
C18H35N7O6 (445.26486900000003)
Ala Ile Ser Arg
C18H35N7O6 (445.26486900000003)
Ala Lys Asp Ile
C19H35N5O7 (445.25363600000003)
Ala Lys Asp Leu
C19H35N5O7 (445.25363600000003)
Ala Lys Glu Val
C19H35N5O7 (445.25363600000003)
Ala Lys Ile Asp
C19H35N5O7 (445.25363600000003)
Ala Lys Leu Asp
C19H35N5O7 (445.25363600000003)
Ala Lys Val Glu
C19H35N5O7 (445.25363600000003)
Ala Leu Asp Lys
C19H35N5O7 (445.25363600000003)
Ala Leu Lys Asp
C19H35N5O7 (445.25363600000003)
Ala Leu Arg Ser
C18H35N7O6 (445.26486900000003)
Ala Leu Ser Arg
C18H35N7O6 (445.26486900000003)
Ala Arg Ile Ser
C18H35N7O6 (445.26486900000003)
Ala Arg Leu Ser
C18H35N7O6 (445.26486900000003)
Ala Arg Ser Ile
C18H35N7O6 (445.26486900000003)
Ala Arg Ser Leu
C18H35N7O6 (445.26486900000003)
Ala Arg Thr Val
C18H35N7O6 (445.26486900000003)
Ala Arg Val Thr
C18H35N7O6 (445.26486900000003)
Ala Ser Ile Arg
C18H35N7O6 (445.26486900000003)
Ala Ser Leu Arg
C18H35N7O6 (445.26486900000003)
Ala Ser Arg Ile
C18H35N7O6 (445.26486900000003)
Ala Ser Arg Leu
C18H35N7O6 (445.26486900000003)
Ala Thr Arg Val
C18H35N7O6 (445.26486900000003)
Ala Thr Val Arg
C18H35N7O6 (445.26486900000003)
Ala Val Glu Lys
C19H35N5O7 (445.25363600000003)
Ala Val Lys Glu
C19H35N5O7 (445.25363600000003)
Ala Val Arg Thr
C18H35N7O6 (445.26486900000003)
Ala Val Thr Arg
C18H35N7O6 (445.26486900000003)
Asp Ala Ile Lys
C19H35N5O7 (445.25363600000003)
Asp Ala Lys Ile
C19H35N5O7 (445.25363600000003)
Asp Ala Lys Leu
C19H35N5O7 (445.25363600000003)
Asp Ala Leu Lys
C19H35N5O7 (445.25363600000003)
Asp Ile Lys Ala
C19H35N5O7 (445.25363600000003)
Asp Lys Ala Ile
C19H35N5O7 (445.25363600000003)
Asp Lys Ala Leu
C19H35N5O7 (445.25363600000003)
Asp Lys Ile Ala
C19H35N5O7 (445.25363600000003)
Asp Lys Leu Ala
C19H35N5O7 (445.25363600000003)
Asp Leu Ala Lys
C19H35N5O7 (445.25363600000003)
Asp Leu Lys Ala
C19H35N5O7 (445.25363600000003)
Glu Ala Lys Val
C19H35N5O7 (445.25363600000003)
Glu Ala Val Lys
C19H35N5O7 (445.25363600000003)
Glu Gly Ile Lys
C19H35N5O7 (445.25363600000003)
Glu Gly Lys Ile
C19H35N5O7 (445.25363600000003)
Glu Gly Lys Leu
C19H35N5O7 (445.25363600000003)
Glu Gly Leu Lys
C19H35N5O7 (445.25363600000003)
Glu Ile Gly Lys
C19H35N5O7 (445.25363600000003)
Glu Ile Lys Gly
C19H35N5O7 (445.25363600000003)
Glu Lys Ala Val
C19H35N5O7 (445.25363600000003)
Glu Lys Gly Ile
C19H35N5O7 (445.25363600000003)
Glu Lys Gly Leu
C19H35N5O7 (445.25363600000003)
Glu Lys Ile Gly
C19H35N5O7 (445.25363600000003)
Glu Lys Leu Gly
C19H35N5O7 (445.25363600000003)
Glu Lys Val Ala
C19H35N5O7 (445.25363600000003)
Glu Leu Gly Lys
C19H35N5O7 (445.25363600000003)
Glu Leu Lys Gly
C19H35N5O7 (445.25363600000003)
Glu Val Ala Lys
C19H35N5O7 (445.25363600000003)
Glu Val Lys Ala
C19H35N5O7 (445.25363600000003)
Gly Glu Ile Lys
C19H35N5O7 (445.25363600000003)
Gly Glu Lys Ile
C19H35N5O7 (445.25363600000003)
Gly Glu Lys Leu
C19H35N5O7 (445.25363600000003)
Gly Glu Leu Lys
C19H35N5O7 (445.25363600000003)
Gly Ile Glu Lys
C19H35N5O7 (445.25363600000003)
Gly Ile Lys Glu
C19H35N5O7 (445.25363600000003)
Gly Ile Arg Thr
C18H35N7O6 (445.26486900000003)
Gly Ile Thr Arg
C18H35N7O6 (445.26486900000003)
Gly Lys Glu Ile
C19H35N5O7 (445.25363600000003)
Gly Lys Glu Leu
C19H35N5O7 (445.25363600000003)
Gly Lys Ile Glu
C19H35N5O7 (445.25363600000003)
Gly Lys Lys Asn
C18H35N7O6 (445.26486900000003)
Gly Lys Leu Glu
C19H35N5O7 (445.25363600000003)
Gly Lys Asn Lys
C18H35N7O6 (445.26486900000003)
Gly Leu Glu Lys
C19H35N5O7 (445.25363600000003)
Gly Leu Lys Glu
C19H35N5O7 (445.25363600000003)
Gly Leu Arg Thr
C18H35N7O6 (445.26486900000003)
Gly Leu Thr Arg
C18H35N7O6 (445.26486900000003)
Gly Asn Lys Lys
C18H35N7O6 (445.26486900000003)
Gly Arg Ile Thr
C18H35N7O6 (445.26486900000003)
Gly Arg Leu Thr
C18H35N7O6 (445.26486900000003)
Gly Arg Thr Ile
C18H35N7O6 (445.26486900000003)
Gly Arg Thr Leu
C18H35N7O6 (445.26486900000003)
Gly Thr Ile Arg
C18H35N7O6 (445.26486900000003)
Gly Thr Leu Arg
C18H35N7O6 (445.26486900000003)
Gly Thr Arg Ile
C18H35N7O6 (445.26486900000003)
Gly Thr Arg Leu
C18H35N7O6 (445.26486900000003)
Ile Ala Asp Lys
C19H35N5O7 (445.25363600000003)
Ile Ala Arg Ser
C18H35N7O6 (445.26486900000003)
Ile Ala Ser Arg
C18H35N7O6 (445.26486900000003)
Ile Asp Ala Lys
C19H35N5O7 (445.25363600000003)
Ile Asp Lys Ala
C19H35N5O7 (445.25363600000003)
Ile Glu Gly Lys
C19H35N5O7 (445.25363600000003)
Ile Glu Lys Gly
C19H35N5O7 (445.25363600000003)
Ile Gly Glu Lys
C19H35N5O7 (445.25363600000003)
Ile Gly Lys Glu
C19H35N5O7 (445.25363600000003)
Ile Gly Arg Thr
C18H35N7O6 (445.26486900000003)
Ile Gly Thr Arg
C18H35N7O6 (445.26486900000003)
Ile Ile Asn Ser
C19H35N5O7 (445.25363600000003)
Ile Ile Ser Asn
C19H35N5O7 (445.25363600000003)
Ile Lys Ala Asp
C19H35N5O7 (445.25363600000003)
Ile Lys Asp Ala
C19H35N5O7 (445.25363600000003)
Ile Lys Glu Gly
C19H35N5O7 (445.25363600000003)
Ile Lys Gly Glu
C19H35N5O7 (445.25363600000003)
Ile Lys Ser Val
Ile Lys Val Ser
Ile Leu Asn Ser
C19H35N5O7 (445.25363600000003)
Ile Leu Ser Asn
C19H35N5O7 (445.25363600000003)
Ile Asn Ile Ser
C19H35N5O7 (445.25363600000003)
Ile Asn Leu Ser
C19H35N5O7 (445.25363600000003)
Ile Asn Ser Ile
C19H35N5O7 (445.25363600000003)
Ile Asn Ser Leu
C19H35N5O7 (445.25363600000003)
Ile Arg Ala Ser
C18H35N7O6 (445.26486900000003)
Ile Arg Gly Thr
C18H35N7O6 (445.26486900000003)
Ile Arg Ser Ala
C18H35N7O6 (445.26486900000003)
Ile Arg Thr Gly
C18H35N7O6 (445.26486900000003)
Ile Ser Ala Arg
C18H35N7O6 (445.26486900000003)
Ile Ser Lys Val
Ile Ser Arg Ala
C18H35N7O6 (445.26486900000003)
Ile Ser Val Lys
Ile Thr Gly Arg
C18H35N7O6 (445.26486900000003)
Ile Thr Arg Gly
C18H35N7O6 (445.26486900000003)
Ile Val Lys Ser
Lys Gly Lys Asn
C18H35N7O6 (445.26486900000003)
Lys Gly Asn Lys
C18H35N7O6 (445.26486900000003)
Lys Ile Ser Val
Lys Ile Val Ser
Lys Lys Gly Asn
C18H35N7O6 (445.26486900000003)
Lys Lys Asn Gly
C18H35N7O6 (445.26486900000003)
Lys Leu Ser Val
Lys Leu Val Ser
Lys Asn Gly Lys
C18H35N7O6 (445.26486900000003)
Lys Asn Lys Gly
C18H35N7O6 (445.26486900000003)
Lys Ser Ile Val
Lys Ser Leu Val
Lys Ser Val Ile
Lys Ser Val Leu
Lys Thr Val Val
Lys Val Ile Ser
Lys Val Leu Ser
Lys Val Ser Ile
Lys Val Ser Leu
Lys Val Thr Val
Lys Val Val Thr
Leu Ala Arg Ser
C18H35N7O6 (445.26486900000003)
Leu Ala Ser Arg
C18H35N7O6 (445.26486900000003)
Leu Gly Arg Thr
C18H35N7O6 (445.26486900000003)
Leu Gly Thr Arg
C18H35N7O6 (445.26486900000003)
Leu Lys Ser Val
Leu Lys Val Ser
Leu Arg Ala Ser
C18H35N7O6 (445.26486900000003)
Leu Arg Gly Thr
C18H35N7O6 (445.26486900000003)
Leu Arg Ser Ala
C18H35N7O6 (445.26486900000003)
Leu Arg Thr Gly
C18H35N7O6 (445.26486900000003)
Leu Ser Ala Arg
C18H35N7O6 (445.26486900000003)
Leu Ser Lys Val
Leu Ser Arg Ala
C18H35N7O6 (445.26486900000003)
Leu Ser Val Lys
Leu Thr Gly Arg
C18H35N7O6 (445.26486900000003)
Leu Thr Arg Gly
C18H35N7O6 (445.26486900000003)
Leu Val Lys Ser
Leu Val Ser Lys
Asn Gly Lys Lys
C18H35N7O6 (445.26486900000003)
Asn Lys Gly Lys
C18H35N7O6 (445.26486900000003)
Asn Lys Lys Gly
C18H35N7O6 (445.26486900000003)
Arg Ala Ile Ser
C18H35N7O6 (445.26486900000003)
Arg Ala Leu Ser
C18H35N7O6 (445.26486900000003)
Arg Ala Ser Ile
C18H35N7O6 (445.26486900000003)
Arg Ala Ser Leu
C18H35N7O6 (445.26486900000003)
Arg Ala Thr Val
C18H35N7O6 (445.26486900000003)
Arg Ala Val Thr
C18H35N7O6 (445.26486900000003)
Arg Gly Ile Thr
C18H35N7O6 (445.26486900000003)
Arg Gly Leu Thr
C18H35N7O6 (445.26486900000003)
Arg Gly Thr Ile
C18H35N7O6 (445.26486900000003)
Arg Gly Thr Leu
C18H35N7O6 (445.26486900000003)
Arg Ile Ala Ser
C18H35N7O6 (445.26486900000003)
Arg Ile Gly Thr
C18H35N7O6 (445.26486900000003)
Arg Ile Ser Ala
C18H35N7O6 (445.26486900000003)
Arg Ile Thr Gly
C18H35N7O6 (445.26486900000003)
Arg Leu Ala Ser
C18H35N7O6 (445.26486900000003)
Arg Leu Gly Thr
C18H35N7O6 (445.26486900000003)
Arg Leu Ser Ala
C18H35N7O6 (445.26486900000003)
Arg Leu Thr Gly
C18H35N7O6 (445.26486900000003)
Arg Ser Ala Ile
C18H35N7O6 (445.26486900000003)
Arg Ser Ala Leu
C18H35N7O6 (445.26486900000003)
Arg Ser Ile Ala
C18H35N7O6 (445.26486900000003)
Arg Ser Leu Ala
C18H35N7O6 (445.26486900000003)
Arg Thr Ala Val
C18H35N7O6 (445.26486900000003)
Arg Thr Gly Ile
C18H35N7O6 (445.26486900000003)
Arg Thr Gly Leu
C18H35N7O6 (445.26486900000003)
Arg Thr Ile Gly
C18H35N7O6 (445.26486900000003)
Arg Thr Leu Gly
C18H35N7O6 (445.26486900000003)
Arg Thr Val Ala
C18H35N7O6 (445.26486900000003)
Arg Val Ala Thr
C18H35N7O6 (445.26486900000003)
Arg Val Thr Ala
C18H35N7O6 (445.26486900000003)
Ser Ala Ile Arg
C18H35N7O6 (445.26486900000003)
Ser Ala Leu Arg
C18H35N7O6 (445.26486900000003)
Ser Ala Arg Ile
C18H35N7O6 (445.26486900000003)
Ser Ala Arg Leu
C18H35N7O6 (445.26486900000003)
Ser Ile Ala Arg
C18H35N7O6 (445.26486900000003)
Ser Ile Lys Val
Ser Ile Arg Ala
C18H35N7O6 (445.26486900000003)
Ser Ile Val Lys
Ser Lys Ile Val
Ser Lys Leu Val
Ser Lys Val Ile
Ser Lys Val Leu
Ser Leu Ala Arg
C18H35N7O6 (445.26486900000003)
Ser Leu Lys Val
Ser Leu Arg Ala
C18H35N7O6 (445.26486900000003)
Ser Leu Val Lys
Ser Arg Ala Ile
C18H35N7O6 (445.26486900000003)
Ser Arg Ala Leu
C18H35N7O6 (445.26486900000003)
Ser Arg Ile Ala
C18H35N7O6 (445.26486900000003)
Ser Arg Leu Ala
C18H35N7O6 (445.26486900000003)
Ser Val Ile Lys
Ser Val Lys Ile
Ser Val Lys Leu
Ser Val Leu Lys
Thr Ala Arg Val
C18H35N7O6 (445.26486900000003)
Thr Ala Val Arg
C18H35N7O6 (445.26486900000003)
Thr Gly Ile Arg
C18H35N7O6 (445.26486900000003)
Thr Gly Leu Arg
C18H35N7O6 (445.26486900000003)
Thr Gly Arg Ile
C18H35N7O6 (445.26486900000003)
Thr Gly Arg Leu
C18H35N7O6 (445.26486900000003)
Thr Ile Gly Arg
C18H35N7O6 (445.26486900000003)
Thr Ile Arg Gly
C18H35N7O6 (445.26486900000003)
Thr Lys Val Val
Thr Leu Gly Arg
C18H35N7O6 (445.26486900000003)
Thr Leu Arg Gly
C18H35N7O6 (445.26486900000003)
Thr Arg Ala Val
C18H35N7O6 (445.26486900000003)
Thr Arg Gly Ile
C18H35N7O6 (445.26486900000003)
Thr Arg Gly Leu
C18H35N7O6 (445.26486900000003)
Thr Arg Ile Gly
C18H35N7O6 (445.26486900000003)
Thr Arg Leu Gly
C18H35N7O6 (445.26486900000003)
Thr Arg Val Ala
C18H35N7O6 (445.26486900000003)
Thr Val Ala Arg
C18H35N7O6 (445.26486900000003)
Thr Val Lys Val
Thr Val Arg Ala
C18H35N7O6 (445.26486900000003)
Thr Val Val Lys
Val Ala Arg Thr
C18H35N7O6 (445.26486900000003)
Val Ala Thr Arg
C18H35N7O6 (445.26486900000003)
Val Ile Lys Ser
Val Ile Ser Lys
Val Lys Ile Ser
Val Lys Leu Ser
Val Lys Ser Ile
Val Lys Ser Leu
Val Lys Thr Val
Val Lys Val Thr
Val Leu Lys Ser
Val Leu Ser Lys
Val Arg Ala Thr
C18H35N7O6 (445.26486900000003)
Val Arg Thr Ala
C18H35N7O6 (445.26486900000003)
Val Ser Ile Lys
Val Ser Lys Ile
Val Ser Lys Leu
Val Ser Leu Lys
Val Thr Ala Arg
C18H35N7O6 (445.26486900000003)
Val Thr Lys Val
Val Thr Arg Ala
C18H35N7O6 (445.26486900000003)
Val Thr Val Lys
Val Val Lys Thr
Val Val Thr Lys
1α,25-dihydroxy-24-oxo-23-azavitamin D2 / 1α,25-dihydroxy-24-oxo-23-azaergocalciferol
C27H43NO4 (445.31919180000006)
1alpha,25-dihydroxy-24-oxo-23-azavitamin D2
C27H43NO4 (445.31919180000006)
tritert-butyl 4-nitro-4-propylhexane-1,1,6-tricarboxylate
(3-decyloxy-2-hydroxypropyl)bis(2-hydroxyethyl)methylammonium methyl sulphate
C19H43NO8S (445.27092380000005)
2-(dimethylamino)ethyl 2-methylprop-2-enoate,2-ethylhexyl prop-2-enoate,styrene
C27H43NO4 (445.31919180000006)
11-(4-Dimethylaminophenyl)-6-methyl-4,5-dihydro(estra-4,9-diene-17,2-(3H)-furan)-3-one
1alpha,25-dihydroxy-24-oxo-23-azavitamin D2/1alpha,25-dihydroxy-24-oxo-23-azaergocalciferol
C27H43NO4 (445.31919180000006)
17-Acetyl-2-(2,2-dimethylmorpholin-4-yl)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-11-one
C27H43NO4 (445.31919180000006)
(5Z,8Z,10E,12E,14Z)-Icosa-5,8,10,12,14-pentaenoylcarnitine
C27H43NO4 (445.31919180000006)
(5Z,8Z,11Z,14Z,17Z)-Icosa-5,8,11,14,17-pentaenoylcarnitine
C27H43NO4 (445.31919180000006)
(8S,9S)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C23H35N5O4 (445.26889100000005)
(8R,9R)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C23H35N5O4 (445.26889100000005)
(8R,9R)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C23H35N5O4 (445.26889100000005)
(8S,9S)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C23H35N5O4 (445.26889100000005)
N-[(2R)-2-[4-(1H-indol-4-yl)-1-piperazinyl]propyl]-N-(2-pyridinyl)cyclohexanecarboxamide
(8R,9R)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C23H35N5O4 (445.26889100000005)
N-[(4R,7R,8R)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide
C24H35N3O5 (445.25765800000005)
(8S,9S)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8S,9S)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8S,9R)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8R,9S)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8R,9S)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8S,9R)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C23H35N5O4 (445.26889100000005)
N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyloxane-4-carboxamide
C24H35N3O5 (445.25765800000005)
N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyloxane-4-carboxamide
C24H35N3O5 (445.25765800000005)
2-[(1R,3R,4aR,9aS)-6-(cyclohexylcarbamoylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-propylacetamide
C24H35N3O5 (445.25765800000005)
2-[(1R,3S,4aR,9aS)-6-(cyclohexylcarbamoylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-propylacetamide
C24H35N3O5 (445.25765800000005)
2-[(1S,3R,4aR,9aS)-6-(cyclohexylcarbamoylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-propylacetamide
C24H35N3O5 (445.25765800000005)
2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-cyclohexylacetamide
C24H35N3O5 (445.25765800000005)
(8S,9R)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C23H35N5O4 (445.26889100000005)
(8R,9S)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C23H35N5O4 (445.26889100000005)
(8S,9R)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8R,9S)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8S,9S)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8R,9R)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyloxane-4-carboxamide
C24H35N3O5 (445.25765800000005)
N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyloxane-4-carboxamide
C24H35N3O5 (445.25765800000005)
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyloxane-4-carboxamide
C24H35N3O5 (445.25765800000005)
N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyloxane-4-carboxamide
C24H35N3O5 (445.25765800000005)
N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyloxane-4-carboxamide
C24H35N3O5 (445.25765800000005)
N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyloxane-4-carboxamide
C24H35N3O5 (445.25765800000005)
2-[(1S,3S,4aS,9aR)-6-[[(cyclohexylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
C24H35N3O5 (445.25765800000005)
2-[(1S,3R,4aS,9aR)-6-(cyclohexylcarbamoylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-propylacetamide
C24H35N3O5 (445.25765800000005)
2-[(1R,3S,4aS,9aR)-6-(cyclohexylcarbamoylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-propylacetamide
C24H35N3O5 (445.25765800000005)
2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide
C24H35N3O5 (445.25765800000005)
2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-cyclohexylacetamide
C24H35N3O5 (445.25765800000005)
(8R,9R)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8S,9R)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8R,9R)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8S,9R)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8R,9S)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8R,9S)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C23H35N5O4 (445.26889100000005)
N-[(5S,6R,9R)-8-[cyclobutyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(5S,6S,9S)-8-[cyclobutyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
N-[(4R,7R,8S)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(4R,7S,8R)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(5S,6S,9S)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C24H35N3O5 (445.25765800000005)
N-[(5R,6S,9S)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C24H35N3O5 (445.25765800000005)
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C24H35N3O5 (445.25765800000005)
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C24H35N3O5 (445.25765800000005)
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C24H35N3O5 (445.25765800000005)
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C24H35N3O5 (445.25765800000005)
N-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5S,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
2-[(1S,3S,4aR,9aS)-6-[[(cyclohexylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
C24H35N3O5 (445.25765800000005)
2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide
C24H35N3O5 (445.25765800000005)
2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide
C24H35N3O5 (445.25765800000005)
1-[(8R,9R,10R)-10-(hydroxymethyl)-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(2-pyridinyl)ethanone
1-[(8S,9R,10R)-10-(hydroxymethyl)-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(2-pyridinyl)ethanone
(8S,9S)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C23H35N5O4 (445.26889100000005)
(8R,9S)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C23H35N5O4 (445.26889100000005)
(8S,9R)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C23H35N5O4 (445.26889100000005)
(8R,9S)-9-[[(4-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C23H35N5O4 (445.26889100000005)
(8S,9R)-9-[[(3-hydroxyphenyl)methyl-methylamino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C23H35N5O4 (445.26889100000005)
N-[(5R,6S,9R)-8-[cyclobutyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(5S,6R,9S)-8-[cyclobutyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(5S,6S,9R)-8-[cyclobutyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(5R,6R,9R)-8-[cyclobutyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(5R,6R,9S)-8-[cyclobutyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide
N-[(4S,7S,8S)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(4S,7R,8R)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(4R,7S,8S)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(4S,7S,8R)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(4S,7R,8S)-5-(2-cyclopropyl-1-oxoethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
C24H35N3O5 (445.25765800000005)
N-[(5R,6R,9R)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C24H35N3O5 (445.25765800000005)
N-[(5R,6R,9S)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C24H35N3O5 (445.25765800000005)
N-[(5S,6R,9R)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C24H35N3O5 (445.25765800000005)
N-[(5R,6S,9R)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C24H35N3O5 (445.25765800000005)
N-[(5S,6R,9S)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C24H35N3O5 (445.25765800000005)
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C24H35N3O5 (445.25765800000005)
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C24H35N3O5 (445.25765800000005)
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C24H35N3O5 (445.25765800000005)
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C24H35N3O5 (445.25765800000005)
N-[(5S,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5R,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
2-[(1R,3R,4aS,9aR)-6-[[(cyclohexylamino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-propylacetamide
C24H35N3O5 (445.25765800000005)
2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide
C24H35N3O5 (445.25765800000005)
2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide
C24H35N3O5 (445.25765800000005)
1-[(8S,9S,10S)-10-(hydroxymethyl)-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(2-pyridinyl)ethanone
1-[(8R,9S,10R)-10-(hydroxymethyl)-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(2-pyridinyl)ethanone
1-[(8S,9R,10S)-10-(hydroxymethyl)-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(2-pyridinyl)ethanone
1-[(8R,9S,10S)-10-(hydroxymethyl)-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(2-pyridinyl)ethanone
3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-4-(trimethylazaniumyl)butanoate
C27H43NO4 (445.31919180000006)
(3R)-18-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyoctadecanoate
(3R,17R)-17-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyoctadecanoate
(4E,8E)-3-hydroxy-2-(undecanoylamino)dodeca-4,8-diene-1-sulfonic acid
C23H43NO5S (445.2861788000001)
(4E,8E)-2-(decanoylamino)-3-hydroxytrideca-4,8-diene-1-sulfonic acid
C23H43NO5S (445.2861788000001)
(E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]dec-4-ene-1-sulfonic acid
C23H43NO5S (445.2861788000001)
4-(2-Heptanoyloxy-3-hexanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C23H43NO7 (445.30393680000003)
4-(2-Octanoyloxy-3-pentanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C23H43NO7 (445.30393680000003)
4-(3-Butanoyloxy-2-nonanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C23H43NO7 (445.30393680000003)
4-(2-Decanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C23H43NO7 (445.30393680000003)
4-(3-Acetyloxy-2-undecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C23H43NO7 (445.30393680000003)
AcCa(20:5)
C27H43NO4 (445.31919180000006)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
3-ethyl-9-methoxy-2-{1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl}-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-10-ol
2-(10-hydroxy-3,7,9,11,13-pentamethyltetradeca-2,5,11-trien-1-yl)-5,6-dimethoxy-3-methylpyridin-4-ol
C27H43NO4 (445.31919180000006)
(1r,2s,6s,9s,11r,14s,15s,18s,20s,23r,24s)-10,20-dihydroxy-6,10,23-trimethyl-17-oxo-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacosan-4-ium-4-olate
C27H43NO4 (445.31919180000006)
(1r,2s,6s,9s,10s,11s,14s,15s,18s,20s,23r,24s)-10,20-dihydroxy-6,10,23-trimethyl-17-oxo-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacosan-4-ium-4-olate
C27H43NO4 (445.31919180000006)
23-isokuroyurinidine
C27H43NO4 (445.31919180000006)
{"Ingredient_id": "HBIN004122","Ingredient_name": "23-isokuroyurinidine","Alias": "NA","Ingredient_formula": "C27H43NO4","Ingredient_Smile": "CC1CC2C(C(C3(O2)CCC4C5CC(C6CC(C(CC6(C5CC4=C3C)C)O)O)O)C)NC1","Ingredient_weight": "445.63","OB_score": "NA","CAS_id": "169786-65-6","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8756","PubChem_id": "101682306","DrugBank_id": "NA"}
alginidine
C27H43NO4 (445.31919180000006)
{"Ingredient_id": "HBIN015126","Ingredient_name": "alginidine","Alias": "NA","Ingredient_formula": "C27H43NO4","Ingredient_Smile": "NA","Ingredient_weight": "445.641","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7039","PubChem_id": "NA","DrugBank_id": "NA"}
alkaloid f4
C27H43NO4 (445.31919180000006)
{"Ingredient_id": "HBIN015171","Ingredient_name": "alkaloid f4","Alias": "NA","Ingredient_formula": "C27H43NO4","Ingredient_Smile": "NA","Ingredient_weight": "445.641","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7023","PubChem_id": "NA","DrugBank_id": "NA"}
alkaloid sn-c
C27H43NO4 (445.31919180000006)
{"Ingredient_id": "HBIN015173","Ingredient_name": "alkaloid sn-c","Alias": "NA","Ingredient_formula": "C27H43NO4","Ingredient_Smile": "NA","Ingredient_weight": "0","OB_score": "NA","CAS_id": "107484-55-9","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7022","PubChem_id": "NA","DrugBank_id": "NA"}
5'-(hydroxymethyl)-7,9,13-trimethyl-5-oxaspiro[pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,2'-piperidin]-18-ene-10,16-diol
C27H43NO4 (445.31919180000006)
2-[(2e,5e,7e)-10-(2,3-dimethyloxiran-2-yl)-10-methoxy-3,7,9-trimethyldeca-2,5,7-trien-1-yl]-5,6-dimethoxy-3-methylpyridin-4-ol
3',6',10,11b-tetramethyl-2,3,3'a,4,4',4a,5,5',6,6',6a,6b,7,7',7'a,8,11,11a-octadecahydro-1h,3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridine]-2,3,5-triol
C27H43NO4 (445.31919180000006)
(2s,3s,3'r,3'as,4as,5r,6's,6ar,6bs,7'as,9r,11as,11br)-3',6',10,11b-tetramethyl-2,3,3'a,4,4',4a,5,5',6,6',6a,6b,7,7',7'a,8,11,11a-octadecahydro-1h,3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridine]-2,3,5-triol
C27H43NO4 (445.31919180000006)
(2s,3s,3's,3'as,4as,5r,6's,6as,6br,7'ar,9r,11as,11br)-3',6',10,11b-tetramethyl-2,3,3'a,4,4',4a,5,5',6,6',6a,6b,7,7',7'a,8,11,11a-octadecahydro-1h,3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridine]-2,3,5-triol
C27H43NO4 (445.31919180000006)
2-[(2e,5e,7r,9s,10r,11e)-10-hydroxy-3,7,9,11,13-pentamethyltetradeca-2,5,11-trien-1-yl]-5,6-dimethoxy-3-methylpyridin-4-ol
C27H43NO4 (445.31919180000006)
(2r,3r,11bs)-3-ethyl-9-methoxy-2-[(1r)-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl]-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-10-ol
1-hydroxy-2,3-dimethoxy-6-[(2e,5e,7e,9s,10s,11e)-10-methoxy-3,7,9,11-tetramethyltrideca-2,5,7,11-tetraen-1-yl]-5-methylpyridin-4-one
(2s,3s,3'r,3'as,4as,5r,6's,6ar,6bs,7'ar,9r,11as,11br)-3',6',10,11b-tetramethyl-2,3,3'a,4,4',4a,5,5',6,6',6a,6b,7,7',7'a,8,11,11a-octadecahydro-1h,3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridine]-2,3,5-triol
C27H43NO4 (445.31919180000006)
(1r,2s,4s,6s,9s,10s,11s,14s,15s,18s,20s,23r,24s)-10,20-dihydroxy-6,10,23-trimethyl-17-oxo-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacosan-4-ium-4-olate
C27H43NO4 (445.31919180000006)
2-[(2e,5e,7z)-10-(3-ethyl-2-methyloxiran-2-yl)-10-hydroxy-3,7,9-trimethyldeca-2,5,7-trien-1-yl]-5,6-dimethoxy-3-methylpyridin-4-ol
1-hydroxy-2,3-dimethoxy-6-[(2z,5z,7z,9s,10s,11z)-10-methoxy-3,7,9,11-tetramethyltrideca-2,5,7,11-tetraen-1-yl]-5-methylpyridin-4-one
(1r,2s,4s,5'r,6r,7s,8r,9s,10r,12s,13r,16s)-5'-(hydroxymethyl)-7,9,13-trimethyl-5-oxaspiro[pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,2'-piperidin]-18-ene-10,16-diol
C27H43NO4 (445.31919180000006)
3-benzyl-1-hydroxy-4,5,10-trimethyl-3h,3ah,6ah,9h,10h,11h,12h,13h,14h-cyclotrideca[d]isoindole-6,17-dione
C29H35NO3 (445.26168000000007)